Lei Wang

Lei Wang

Auto-generated profile, based on publicly available information

Lei Wang

Department of Gastrointestinal Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
YLYing Lv
Ying Lv
XWXin Wang
Xin Wang
LLLerong Liang
Lerong Liang
LWLei Wang
Lei Wang
JLJie Lu
Jie Lu
Purpose: The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients. Materials and methods: One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before operation, then KRAS mutation status was analyzed through pathologically confirmed CRC samples. The association between tumor clinical characteristics and PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax), SUVmean, and metabolic tumor volume (MTV), and KRAS mutation status was analyzed using chi-squared tests, Mann–Whitney U tests, and logistic regression analysis. Results: The KRAS mutation type patients exhibited high MTV and high SUVmax using a threshold of 17.8 cm3 and 8.7 respectively and the predictive accuracy was 0.772 and 0.603 respectively. High MTV (P=0.001; 95% CI: 1.119–1.296) and high SUVmax (P=0.048; 95% CI: 0.564–0.985) were independent predictors for KRAS mutation status. Conclusion: MTV and SUVmax were associated with KRAS mutation type in CRC patients. PET/CT metabolic parameters can be used for supplementing KRAS mutation status prediction in CRC patients.

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YDYanghong Deng
Yanghong Deng
CPChi Pan
Chi Pan
PLPing Lan
Ping Lan
LWLei Wang
Lei Wang
WCWeiqing Chen
Weiqing Chen
JWJianping Wang
Jianping Wang
3502Background: The FOWARC trial compared FOLFOX6 with or without Radiation in neoadjuvant treatment of locally advanced rectal cancer to 5-FU chemoradiotherapy. First results of early secondary en...

19 October 2022 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
ZLZheng-Hui Liu
Zheng-Hui Liu
HWHui-Ju Wang
Hui-Ju Wang
LWLei Wang
Lei Wang
GRGuo-Qing Ru
Guo-Qing Ru
YWYuan-yu Wang
Yuan-yu Wang
Aim. To explore the correlations between the expression of zinc finger protein 521 (ZNF521) with immune invasion and prognosis of gastric cancer. Methods. Expression of ZNF521 was examined by immunohistochemistry in gastric cancer cases. KaplanMeier plotter was used to determine the relationships between ZNF521 and prognosis. TIMER and GEPIA were used to analyze the correlation between ZNF521 expression and gene markers of immune cell infiltration. Results. The expression of ZNF521 was up-regulated in gastric cancer samples. KaplanMeier analysis indicated that higher expression of ZNF521 was associated with poor prognosis. The expression of ZNF521 was correlated with infiltrating levels of CD4+ T and CD8+ T cells, macrophages, neutrophils, and dendritic cells in gastric cancer, which also correlated with diverse immune marker sets. Conclusions. ZNF521 is correlated significantly with immune cell infiltration and is a valuable biomarker for prognosis in gastric cancer.

30 April 2020 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
LWLei Wang
Lei Wang
YLYing Lv
Ying Lv
GLGuoqin Liu
Guoqin Liu

11 January 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
YWYing Wang
Ying Wang
LWLei Wang
Lei Wang
MLManfei Liang
Manfei Liang
ZXZhongkai Xu
Zhongkai Xu
YXYiheng Xue
Yiheng Xue
GLGuoqin Liu
Guoqin Liu
We aimed to investigate manual subtraction computed tomography angiography (MS-CTA) to further confirm the distribution and classification of LCA (left colic artery) ascending/descending branches, then observe the postoperative blood flow path to illustrate how the above branches evolved to postoperative blood path. 89 patients with distal sigmoid and rectal cancer were referred in our observation and underwent MS-CTA between June 2020 and March 2022. We classified the distribution of LCA and confirmed whether there exists AMCA (accessory middle colic artery). Then we planned blood flow path based on the classification of LCA branches before operation. High ligation was applied in regular radical surgery. During operation, we carefully protect the bifurcation of ascending and descending LCA. Then we compared the planned blood flow path with the actual postoperative blood flow path to verify the mechanism we proposed previously. Of 89 patients, 82 cases met our criteria, we summarized 6 distribution pattens of LCA ascending and descending branches. These preoperative pattens are consistent with the inspection during operation. The postoperative blood flow path of 6 pattens is evolved from the above adjacent anastomotic branches and is consistent with the planned blood flow path. We also found 2 cases with IMA stenosis and 1 case with SMA stenosis under pathological condition, and their compensatory blood flow path is in accordance with our theory. The rate of the anastomotic leakage in our study group is relatively low (7.3%). MS-CTA could confirm the distribution of LCA and AMCA, display accurate postoperative blood reconstruction path after IMA high ligation, and it further verified the mechanism we proposed previously, which is the proximal anastomotic branches forming new blood flow path from high-pressure area to the low-pressure area. This mechanism might be helpful for performing accurate laparoscopic sigmoid and rectal cancer surgery.

10 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LCLin Chen
Lin Chen
DSDandan Song
Dandan Song
SHShufu Hou
Shufu Hou
ALAiju Liu
Aiju Liu
JGJing Gao
Jing Gao
LWLei Wang
Lei Wang
Background: Lung cancer (LC) remains the leading cause of cancer-related death worldwide. While immune checkpoint inhibitors (ICIs) have demonstrated survival benefits in advanced-stage disease, treatment responses exhibit significant heterogeneity across patients. The potential role of comorbid chronic obstructive pulmonary disease (COPD) in modulating survival outcomes from ICIs therapy remains controversial, with conflicting evidence regarding its synergistic or antagonistic effects. This meta-analysis systematically evaluates the impact of COPD on survival outcomes in lung cancer patients receiving ICIs, aiming to clarify its prognostic value and guide precision immunotherapy strategies. Methods: We systematically searched PubMed, Cochrane Library, CNKI, and EMBASE for studies published up to March 31, 2025, to evaluate the synergistic survival impact of comorbid COPD in lung cancer patients receiving ICIs. Primary outcomes included overall survival (OS) and progression-free survival (PFS). Results: This study pooled data from 10 studies (N = 6,909) to assess the impact of comorbid COPD on survival outcomes among LC patients receiving ICIs. The meta-analysis revealed that LC patients with comorbid COPD showed significant improvements in OS (HR = 0.90, 95% CI: 0.85–0.96, p < 0.001) and PFS (HR = 0.54, 95% CI: 0.44–0.67, p < 0.001) compared to those without COPD. Notably, while bias analysis for PFS indicated potential bias, inter-subgroup heterogeneity was negligible (I² = 0%). Conclusions: This study demonstrated that the presence of comorbid COPD was associated with significantly improved overall survival in lung cancer patients receiving ICIs. Although a significant progression-free survival benefit was also observed, this result may be influenced by potential publication bias. Further prospective studies that incorporate comprehensive biomarker analyses are warranted to validate the observed COPD-ICIs interaction and to develop optimized, personalized treatment strategies for this patient population. Systematic Review Registration: www.inplasy.com , identifier INPLASY202580086.